A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.
Seth Augenstein
Advertisement
Articles by Seth Augenstein
A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.
Advertisement
Latest Updated Articles
Ovarian Suppression Combined with Tamoxifen May Help Premenopausal PatientsSeptember 27th 2019
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Managing Rash and Stomatitis With Daraxonrasib in Pancreatic Cancer
2
FDA Approves Oral Nilotinib Tablets for Ph+ CML
3
Nursing Guide to Managing Lorlatinib in ALK+ NSCLC: 7-Year CROWN Insights
4
GLP-1 RAs Linked to Lower HR+ Breast Cancer Risk and Improved Survival
5